Home/Filings/4/0001209191-22-035443
4//SEC Filing

Currie Mark G 4

Accession 0001209191-22-035443

CIK 0001446847other

Filed

Jun 8, 8:00 PM ET

Accepted

Jun 9, 5:04 PM ET

Size

9.2 KB

Accession

0001209191-22-035443

Insider Transaction Report

Form 4
Period: 2022-06-07
Currie Mark G
Chief Scientific Officer
Transactions
  • Exercise/Conversion

    Class A Common Stock

    2022-06-07$11.65/sh+190,383$2,217,962782,141 total
  • Exercise/Conversion

    Employee Stock Option (Right to Buy)

    2022-06-07190,3830 total
    Exercise: $11.65Exp: 2023-02-01Class A Common Stock (190,383 underlying)
  • Sale

    Class A Common Stock

    2022-06-07$12.01/sh190,383$2,286,500591,758 total
Footnotes (3)
  • [F1]This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
  • [F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.00 to $12.05, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  • [F3]The option, vested as to 1.25% on each monthly anniversary of the vesting commencement date for the first 36 months, and as to 4.5833% of the award on each monthly anniversary thereafter, is presently exercisable in full.

Issuer

IRONWOOD PHARMACEUTICALS INC

CIK 0001446847

Entity typeother

Related Parties

1
  • filerCIK 0001478244

Filing Metadata

Form type
4
Filed
Jun 8, 8:00 PM ET
Accepted
Jun 9, 5:04 PM ET
Size
9.2 KB